Faron Pharmaceuticals Oy Holding(s) in Company (4814P)
February 17 2021 - 10:30AM
UK Regulatory
TIDMFARN
RNS Number : 4814P
Faron Pharmaceuticals Oy
17 February 2021
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Holding(s) in the Company
Company announcement, 17 February 2021 at 4.30pm GMT / 6.30pm
EET
TURKU - FINLAND - Faron Pharmaceuticals Oy (First North: FARON,
AIM: FARN), the clinical stage biopharmaceutical company, has on 16
February 2021 received notifications from Mr. Timo Syrjälä and Mr.
Tom-Erik Lind of the decrease of their holdings due to issuance of
new shares.
Trading in the Placing Shares commenced on First North and AIM
on 16 February 2021.
The mentioned notifications are attached in this
announcement.
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: + 44 207 213 0880
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 40 555 4727
Jukka Järvelä
Phone: +358 50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Stern Investor Relations
Julie Seidel, Naina Zaman
Phone: +1 (212) 362-1200
E-mail: julie.seidel@sternir.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs. The Company currently has
a pipeline based on the receptors involved in regulation of immune
response in oncology and organ damage. Bexmarilimab is its
investigative precision immunotherapy with the potential to provide
permanent immune stimulation for difficult-to-treat cancers through
targeting myeloid function. A novel anti-Clever-1 humanised
antibody, bexmarilimab targets Clever-1 positive (Common Lymphatic
Endothelial and Vascular Endothelial Receptor 1) tumour associated
macrophages (TAMs) in the tumour microenvironment, converting these
highly immunosuppressive M2 macrophages to immune stimulating M1
macrophages. With the ability to switch immune suppression to
immune activation in various conditions, bexmarilimab has potential
across oncology, infectious diseases and vaccine development.
Currently in phase I/II clinical development as a potential therapy
for patients with untreatable solid tumours, bexmarilimab has
potential as a single-agent therapy or in combination with other
standard treatments including immune checkpoint molecules.
Traumakine is an investigational intravenous (IV) interferon
beta-1a therapy for the treatment of acute respiratory distress
syndrome (ARDS) and other ischemic or hyperinflammatory conditions.
In addition to its profound antiviral effect, Traumakine
upregulates the cell surface protein Cluster of Differentiation 73
(CD73), an enzyme that suppresses pro-inflammatory responses in
endothelial cells. Using an IV administration of interferon beta-1a
provides optimal exposure to the lung vasculature, increasing
protection against serious lung complications and helping to
prevent vascular leakage by enhancing endothelial barrier function.
Traumakine is currently being evaluated in global trials as a
potential treatment for hospitalised patients with COVID-19. As
part of a working relationship established with Faron, the 59th
Medical Wing of the US Air Force and the US Department of Defense
are also evaluating Traumakine's role in preventing multiple organ
dysfunction syndrome (MODS) after ischemia-reperfusion injury
caused by a major trauma. Faron is based in Turku, Finland. Further
information is available at www.faron.com .
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the Faron Pharmaceuticals Ltd
underlying issuer of existing shares
to which voting rights are attached
(ii) :
-------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer X
-----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights
-----
An acquisition or disposal of financial instruments
-----
An event changing the breakdown of voting rights
-----
Other (please specify)(iii) : (Decrease of holding due to issuance X
of new shares)
-----
3. Details of person subject to the notification obligation (iv)
Name
Timo Syrjälä
City and country of registered office
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v)
Name
-------------------------------------------
City and country of registered office
(if applicable)
-------------------------------------------
5. Date on which the threshold was 12.2.2021
crossed or reached (vi) :
-------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 16.2.2021
-------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer (vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 13.57 13.57 50,417,874
------------------ --------------------- -------------- --------------------
Position of
previous notification
(if
applicable) 14.08% 14.08%
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares (ix)
ISIN code (if
possible)
--------------------------------------------------
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
---------------------- -------------------------- ------------------------- ---------------------
FI4000153309 2,561,402 4,277,837 5.08% 8.48%
---------------------- -------------------------- ------------------------- ---------------------
SUBTOTAL 8.
A 6,839,239 13.57%
-------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting rights
financial date Conversion Period rights that may
instrument (x) (xi) be acquired if
the instrument
is
exercised/converted.
----------- ------------------------------ -------------------------------- ---------------------
SUBTOTAL 8. B 1
------------------------------ -------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to Art.
13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting rights
financial date (x) Conversion cash voting rights
instrument Period (xi) settlement
(xii)
---------------- -------------------- -------------------- --------------------
SUBTOTAL 8.B.2
-------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer(xiii)
Full chain of controlled undertakings through which the voting rights X
and/or the financial instruments are effectively held starting with
the ultimate controlling natural person or legal entity(xiv) (please
add additional rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is higher
is higher than the instruments if it than the notifiable
notifiable threshold equals or is higher threshold
than the notifiable
threshold
---------------------- --------------------- --------------------------
Timo Syrjälä
(Direct) 5.08% 5.08%
---------------------- --------------------- --------------------------
Acme Investments
SPF Sarl (Indirect) 8.48% 8.48%
---------------------- --------------------- --------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
-------------------------------------------------
The number and % of voting rights
held
-------------------------------------------------
The date until which the voting rights
will be held
-------------------------------------------------
11. Additional information (xvi)
Decrease due to issuance of shares
Place of completion Luxembourg
Date of completion 16.02.2021
-----------
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the Faron Pharmaceuticals Ltd
underlying issuer of existing shares
to which voting rights are attached
(ii) :
-------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer X
-----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights
-----
An acquisition or disposal of financial instruments
-----
An event changing the breakdown of voting rights
-----
Other (please specify)(iii) : (Decrease of holding due to issuance x
of new shares)
-----
3. Details of person subject to the notification obligation (iv)
Name
Tom-Erik Lind
City and country of registered office
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v)
Name
-------------------------------------------
City and country of registered office
(if applicable)
-------------------------------------------
5. Date on which the threshold was 12.2.2021
crossed or reached (vi) :
-------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 16.2.2021
-------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer (vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 7.55 7.55 50,417,874
------------------ --------------------- -------------- --------------------
Position of
previous notification
(if
applicable) 10.00% 10.00%
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares (ix)
ISIN code (if
possible)
--------------------------------------------------
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
---------------------- -------------------------- ------------------------- ---------------------
FI4000153309 3,806,611 7.55
---------------------- -------------------------- ------------------------- ---------------------
SUBTOTAL 8.
A 3,806,611 7.55%
-------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting rights
financial date Conversion Period rights that may
instrument (x) (xi) be acquired if
the instrument
is
exercised/converted.
----------- ------------------------------ -------------------------------- ---------------------
SUBTOTAL 8. B 1
------------------------------ -------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to Art.
13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting rights
financial date (x) Conversion cash voting rights
instrument Period (xi) settlement
(xii)
---------------- -------------------- -------------------- --------------------
SUBTOTAL 8.B.2
-------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled X
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer(xiii)
Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with
the ultimate controlling natural person or legal entity(xiv) (please
add additional rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is higher
is higher than the instruments if it than the notifiable
notifiable threshold equals or is higher threshold
than the notifiable
threshold
----------------------- --------------------- --------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
-------------------------------------------------
The number and % of voting rights
held
-------------------------------------------------
The date until which the voting rights
will be held
-------------------------------------------------
11. Additional information (xvi)
Place of completion Malta
Date of completion 16.2.2021
----------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLZZGMZVNFGMZM
(END) Dow Jones Newswires
February 17, 2021 11:30 ET (16:30 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024
